This Journal has an Open Access Option
Celebrating 20 Years and Increased Frequency - 10 issues in 2010!
Strong Immune Response to New siRNA Drugs in Development May Cause Toxic Side Effects
The Official Journal of Oligonucleotide Therapeutics Society (OTS)
Join today and begin receiving benefits of membership!
Oligonucleotides is the leading peer-reviewed journal that presents the latest research on oligonucleotide drug development. The Journal’s scope focuses not only on antisense oligonucleotides, but also on tracking advances in the development of ribozymes, immune stimulatory CpG oligos, and therapeutic RNAi.
The only journal to focus solely on therapeutic oligonucleotides, while also covering:
• The full spectrum of oligonucleotide drug applications
• A broad view of oligonucleotide drug development
• The use of nucleic acids or related compounds to alter gene expression
• Synthetic oligonucleotides, including RNA, DNA, and ribozymes both in vitro and in vivo
Join OTS or Renew Your Membership and receive electronic access to all available papers online, as well as four print issues per year. (Click here for a PDF with membership benefits and order form)
Latest Impact Factor* is 2.507
* 2009 Journal Citation Reports® published by Thomson Reuters, 2010
Indexed/Abstracted in:
MEDLINE; Current Contents®/Life Sciences; EMBASE/Excerpta Medica; Science Citation Index Expanded; Science Citation Index®; BIOSIS Previews; SIIC Databases; Biotechnology Citation Index®; Biological Abstracts; EMBiology; Scopus